Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician

BJU International
Christopher R Chapple

Abstract

Less than 10 years ago surgery and watchful-waiting were the only widely accepted management options for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and benign prostatic obstruction (BPO). There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH/LUTS; this has arguably therefore been the most major change in urological clinical practice in the last decade. Currently alpha(1)-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5alpha-reductase inhibitors (finasteride, dutasteride) are another option for BPH/LUTS, which reduce prostatic mass and therefore the mechanical or 'static' component of BPO. In the last 10 years there have been four direct comparative studies between alpha(1)-adrenoceptor antagonists and finasteride, including their combination, the results of which, and their implications for therapy, are discussed. Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existi...Continue Reading

Associated Clinical Trials

References

Oct 22, 1992·The New England Journal of Medicine·G J GormleyJ S Tenover
Dec 1, 1990·The Journal of Clinical Endocrinology and Metabolism·J Geller
Apr 9, 1994·BMJ : British Medical Journal·P Abrams
Apr 3, 2003·Urology·Franklin C LoweUNKNOWN Finasteride Study Group
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group

❮ Previous
Next ❯

Citations

Jul 29, 2009·International Urogynecology Journal and Pelvic Floor Dysfunction·Daniel AltmanChristian Falconer
Jun 1, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Karen P Kerr
Sep 2, 2010·The British Journal of Nutrition·Ales VidlarVilim Simanek
Feb 28, 2008·Nature Clinical Practice. Urology·Anand K Patel, Christopher R Chapple
Jun 27, 2007·Prostate Cancer and Prostatic Diseases·M P O'LearyL Black
Sep 9, 2006·BMJ : British Medical Journal·Anand K Patel, Christopher R Chapple
May 20, 2006·World Journal of Urology·Abdel-Rahmène AzzouziAlexandre de la Taille
Oct 1, 2006·Expert Opinion on Drug Discovery·Anna MinariniCarlo Melchiorre
Jul 1, 2015·Sexual Medicine Reviews·Chris G McMahon
May 21, 2010·The Journal of Urology·Brian T HelfandKevin T McVary
Mar 26, 2010·Autonomic Neuroscience : Basic & Clinical·Hiroshi NagabukuroCatherine Abbadie
Oct 11, 2005·Mayo Clinic Proceedings·Thomas J Beckman, Lance A Mynderse
Feb 19, 2008·The Journal of Urology·Chris MullinsUNKNOWN MPSA Consortium
Dec 18, 2007·The Journal of Urology·Kimio SugayaYoshihide Ogawa
Jun 23, 2007·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Michiko OkaKenji Kuwabara
Nov 17, 2011·International Neurourology Journal·Kang Jun ChoJoon Chul Kim
Oct 13, 2006·Radiologic Clinics of North America·Alexander KutikovS Bruce Malkowicz
Dec 22, 2004·BJU International·Michael Wyllie
Jul 28, 2007·Journal of the American Academy of Nurse Practitioners·Muta M Issa, Kate H Kraft
Feb 4, 2010·Neurourology and Urodynamics·Anastasios Athanasopoulos
Apr 24, 2016·Current Urology Reports·Michelle HerbertsTobias Köhler
Sep 9, 2008·Urology·José Augusto F BittencourtRoberto Soares de Moura
Nov 10, 2017·American Journal of Physiology. Renal Physiology·Zongwei Wang, Aria F Olumi
Nov 2, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Robert KüglerRalf Middendorff
Jan 1, 2012·Lower Urinary Tract Symptoms·Saori NishijimaHideyuki Yamamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.